GeneDx Holdings (WGS) Receivables - Other (2020 - 2023)

GeneDx Holdings has disclosed Receivables - Other across 4 years of filings, most recently posting $2.9 million for Q2 2023.

• In Q2 2023, Receivables - Other fell 33.53% year-over-year to $2.9 million; the TTM figure through Jun 2023 stood at $2.9 million (down 33.53% YoY), while the FY2022 annual figure was $1.5 million, up 2677.78% from the prior year.
• Receivables - Other climbed to $2.9 million in Q2 2023, from $636000.0 in the prior quarter.
• Over the last five years, Receivables - Other for WGS reached as high as $4.4 million in Q2 2022 and fell as low as $54000.0 in Q4 2021.
• The 4-year median for Receivables - Other is $1.5 million (2022), against an average of $1.9 million.
• Annual changes were most pronounced in 2021 — Receivables - Other sank 97.34% — and 2022, when it soared 2677.78%.
• A 4-year view of Receivables - Other shows it stood at $2.0 million in 2020, then slumped by 97.34% to $54000.0 in 2021, then soared by 2677.78% to $1.5 million in 2022, then surged by 93.33% to $2.9 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.9 million, $636000.0, and $1.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.